FEAR & GREED | Business News Q+A: The GLP-1 drugs changing health and markets
Jan 29, 2026
Dr Zac Turner, medical doctor and biomedical scientist, explains GLP-1 drugs and their origins in diabetes treatment. He covers rapid weight-loss effects and risks like muscle and bone loss. He discusses uncertainty around long-term health endpoints, off-label and microdosing uses, and next-generation drugs targeting multiple receptors and market implications.
AI Snips
Chapters
Transcript
Episode notes
Origins And Trial Bias
- GLP-1 drugs began as diabetes treatments and unexpectedly caused large weight loss in users.
- Early trials were company-funded so results emphasized weight loss without full long-term harms or benefits.
Weight Loss ≠ Health Gain
- Large short-term weight loss often included muscle and bone loss, not just fat reduction.
- Key unknowns remain about long-term endpoints like heart attacks, strokes, dementia and lifespan.
Consult And Protect Muscle
- Talk to a doctor before starting GLP-1 drugs and consider microdosing options some practitioners use off-label.
- Monitor muscle mass and aim to limit weight loss to under ~0.5 kg per week after initial weeks to preserve muscle.